Publication: Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative
1
Issued Date
2020-05-21
Resource Type
ISSN
22192840
Other identifier(s)
2-s2.0-85085854181
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
World journal of gastroenterology. Vol.26, No.19 (2020), 2416-2426
Suggested Citation
Panyavee Pitisuttithum, Wah Kheong Chan, George Boon Bee Goh, Jian Gao Fan, Myeong Jun Song, Phunchai Charatcharoenwitthaya, Ajay Duseja, Yock Young Dan, Kento Imajo, Atsushi Nakajima, Khek Yu Ho, Khean Lee Goh, Vincent Wai Sun Wong, Sombat Treeprasertsuk Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. World journal of gastroenterology. Vol.26, No.19 (2020), 2416-2426. doi:10.3748/wjg.v26.i19.2416 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/58154
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative
Other Contributor(s)
Graduate School of Medicine
Shanghai Jiao Tong University School of Medicine
University of Malaya
Chulalongkorn University
Singapore General Hospital
National University of Singapore
Faculty of Medicine, Siriraj Hospital, Mahidol University
The Catholic University of Korea
Chinese University of Hong Kong
Postgraduate Institute of Medical Education & Research, Chandigarh
Shanghai Jiao Tong University School of Medicine
University of Malaya
Chulalongkorn University
Singapore General Hospital
National University of Singapore
Faculty of Medicine, Siriraj Hospital, Mahidol University
The Catholic University of Korea
Chinese University of Hong Kong
Postgraduate Institute of Medical Education & Research, Chandigarh
Abstract
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. BACKGROUND: Gamma-glutamyl transferase (GGT) is associated with the risk of cardiovascular disease (CVD) in the general population. AIM: To identify the association of baseline GGT level and QRISK2 score among patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD). METHODS: This was a retrospective study involving 1535 biopsy-proven NAFLD patients from 10 Asian centers in 8 countries using data collected by the Gut and Obesity in Asia (referred to as "GO ASIA") workgroup. All patients with available baseline GGT levels and all 16 variables for the QRISK2 calculation (QRISK2-2017; developed by researchers at the United Kingdom National Health Service; https://qrisk.org/2017/; 10-year cardiovascular risk estimation) were included and compared to healthy controls with the same age, sex, and ethnicity. Relative risk was reported. QRISK2 score > 10% was defined as the high-CVD-risk group. Fibrosis stages 3 and 4 (F3 and F4) were considered advanced fibrosis. RESULTS: A total of 1122 patients (73%) had complete data and were included in the final analysis; 314 (28%) had advanced fibrosis. The median age (interquartile range [IQR]) of the study population was 53 (44-60) years, 532 (47.4%) were females, and 492 (43.9%) were of Chinese ethnicity. The median 10-year CVD risk (IQR) was 5.9% (2.6-10.9), and the median relative risk of CVD over 10 years (IQR) was 1.65 (1.13-2.2) compared to healthy individuals with the same age, sex, and ethnicity. The high-CVD-risk group was significantly older than the low-risk group (median [IQR]: 63 [59-67] vs 49 [41-55] years; P < 0.001). Higher fibrosis stages in biopsy-proven NAFLD patients brought a significantly higher CVD risk (P < 0.001). Median GGT level was not different between the two groups (GGT [U/L]: Median [IQR], high risk 60 [37-113] vs low risk 66 [38-103], P = 0.56). There was no correlation between baseline GGT level and 10-year CVD risk based on the QRISK2 score (r = 0.02). CONCLUSION: The CVD risk of NAFLD patients is higher than that of healthy individuals. Baseline GGT level cannot predict CVD risk in NAFLD patients. However, advanced fibrosis is a predictor of a high CVD risk.